SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalCLSN


From: John D. White11/23/2012 3:55:41 PM
   of 5
 
Well, I've seen this movie before. In DNDN at 6 out at 9 then it soars over 40. Pull up a ten year chart on it.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: John D. White who wrote (1)11/26/2012 10:27:10 AM
From: Glenn Petersen
   of 5
 
CLSN's rally has carried over into Monday morning:

<snip>

Celsion Corporation (NASDAQ: CLSN) also made an enormous recovery too, moving up an incredible 45% in the last five trading sessions and roughly 20% throughout last week. CLSN is now 22.4% higher than it was after initial coverage by Bio-Wire on October 1st, 2012 which claimed that the stock was generating bullish potential based on the upcoming phase III clinical trial results of the HEAT study - the study that will provide results that will be used in the eventual NDA for Celsion's flagship product ThermoDox for the treatment of liver cancer.

Since liver cancer is one of the most challenging types of cancer to treat, and since unmet demand is already enormous (and growing) for this particularly disease, ThermoDox has very exciting prospects given that it can provide a favorable efficacy and safety profile when we see the data in December 2012. A recent article on Option Monster also caught my attention, since it alerted me to some really serious buying in call options that are set to expire in January and February. There is clearly some interest in CLSN stock, anticipating the upcoming clinical trial data for ThermoDox. Momentum traders should consider CLSN since it seems that there is strong bias on the bullish side as we wait - particularly in the options market.

<snip>

seekingalpha.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Glenn Petersen who wrote (2)12/27/2012 6:45:49 PM
From: John D. White
   of 5
 
Covered market shorts today after HR got done babbling about FC (BTW, thanks harry) and rolled some proceeds into another 1000 (at 7.89). No CC's on this lot. Tape action looks convincing to me.

Now that I've had a chance to look into it, I think it has better than the normal 30:1 biotec statistical odds since it's really not a drug. It's still $40 or $1 come end of trial. Just a higher probability for the former IMHO.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: John D. White who wrote (3)1/31/2013 6:11:07 AM
From: John D. White
   of 5
 
Well, well now.

It's show time.

6:00 AM 1.31.13

Good news in two hours and I will no longer be talking to myself. The mother of all short squeezes will unleash. It will be historic, no kidding.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: John D. White who wrote (4)1/31/2013 10:03:20 AM
From: Glenn Petersen
   of 5
 
InPlay 7:38AM Celsion trading down 84% on disappointing Phase III data on ThermoDox in Primary Liver Cancer; Study did not provide sufficient evidence of clinical effectiveness ( CLSN) 8.02 :
  • See 6:06 comment for detail.
  • Stock is trading at 1.25 in pre-mkt.
  • Company to host conference call at 8:00 AM EST today

Share RecommendKeepReplyMark as Last Read